New hope for Drug-Resistant TB: shorter Pill-Only regimen tested
NCT ID NCT03828201
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This study tests a new combination of five oral drugs (bedaquiline, delamanid, levofloxacin, linezolid, and clofazimine) for treating multidrug-resistant tuberculosis (MDR-TB). The goal is to see if a shorter treatment course (16 to 40 weeks) can effectively cure the infection with fewer side effects. About 271 participants aged 12 and older with MDR-TB will be enrolled. The study compares different treatment lengths to find the best balance of effectiveness and safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS, MULTIDRUG-RESISTANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Lung Hospital, Hanoi Lung Hospital
Hanoi, Vietnam
-
TB-HIV Innovations & Clinical Research Foundation Corp
Silang, 4114, Philippines
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sputum DNA test aims to outsmart Drug-Resistant TB
- Can a shorter TB drug combo beat Drug-Resistant TB?
- New TB test could speed up detection of Drug-Resistant strains
- TB study aims to unlock secrets of the disease
- New hope for Drug-Resistant TB: shorter, safer treatment on the horizon?
- New hope for kids with Drug-Resistant TB: bedaquiline trial launches